{
  "Global": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "North America": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "Europe": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "Asia Pacific": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "Latin America": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "Middle East": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  },
  "Africa": {
    "By Product Type": {
      "Microbiome Modulators": {
        "Postbiotics": {},
        "Soluble Microbial Products/Metabolite": {}
      }
    },
    "By Therapeutic Area": {
      "Gastrointestinal Disorders": {
        "C. difficile Infection (CDI)": {},
        "Inflammatory Bowel Disease (IBD)": {},
        "Irritable Bowel Syndrome (IBS)": {}
      },
      "Metabolic Disorders": {
        "Type 2 Diabetes": {},
        "Obesity": {},
        "Nonalcoholic Steatohepatitis (NASH)": {}
      },
      "Oncology": {
        "Immuno-oncology": {},
        "Managing Chemotherapy Side Effects": {}
      },
      "Autoimmune & Central Nervous System Disorders": {
        "Multiple Sclerosis": {},
        "Rheumatoid Arthritis": {},
        "Autism Spectrum Disorder (ASD)": {},
        "Parkinson's Disease": {}
      },
      "Infectious Diseases": {
        "Multi-Drug Resistant (MDR) Pathogen Infections": {},
        "Helicobacter pylori infection": {}
      }
    },
    "By Microbiome Target Site": {},
    "By Route of Administration": {},
    "By End User": {},
    "By Region": {
      "North America": {
        "U.S.": {},
        "Canada": {}
      },
      "Europe": {
        "U.K.": {},
        "Germany": {},
        "Italy": {},
        "France": {},
        "Spain": {},
        "Russia": {},
        "Rest of Europe": {}
      },
      "Asia Pacific": {
        "China": {},
        "India": {},
        "Japan": {},
        "South Korea": {},
        "ASEAN": {},
        "Australia": {},
        "Rest of Asia Pacific": {}
      },
      "Latin America": {
        "Brazil": {},
        "Argentina": {},
        "Mexico": {},
        "Rest of Latin America": {}
      },
      "Middle East": {
        "GCC": {},
        "Israel": {},
        "Rest of Middle East": {}
      },
      "Africa": {
        "North Africa": {},
        "Central Africa": {},
        "South Africa": {}
      }
    }
  }
}